Alzheimer's disease (AD) remains an incurable disease and lacks efficient diagnostic
methods. Most AD treatments have focused on amyloid-β (Aβ) targeted therapy; however, it …

With the failure of various amyloid-β-targeted drugs for Alzheimer's disease (AD) in clinical
trials, tau protein has gained growing attention as an alternative therapeutic target in recent …

Efficient multi-targeted intervention of complex pathogenic factors may hold promises for
Alzheimer's disease (AD) treatment due to the continuous failure of single-targeted therapy …

Background Although many therapeutic strategies for Alzheimer's disease (AD) have been
explored, these strategies are seldom used in the clinic. Therefore, AD therapeutic research …

The hyperphosphorylated and aggregated tau accumulation represents a significant
pathological hallmark of tauopathies including Alzheimer's disease (AD), which is highly …

The Alzheimer's disease (AD) therapeutic research is yielding a large number of potent
molecules. The nanoparticle-based therapeutics against the protein aggregation in AD is …

Inflammatory responses, manifested in excessive oxidative stress and microglia
overactivation, together with metal ion-triggered amyloid-beta (Aβ) deposition, are critical …

Alzheimer's disease (AD) is a progressive and irreversible brain disorder. Recent studies
revealed the pivotal role of β-amyloid (Aβ) in AD. However, there is no conclusive indication …

Alzheimer's disease (AD), the most common form of dementia, is characterized by
extracellular β-amyloid plaques and intracellular neurofibrillary tangles (NFTs), which are …

Alzheimer's disease (AD) remains the most prevalent neurodegenerative disease, and no
effective treatment is available yet. Metal‐ion‐triggered aggregates of amyloid‐beta (Aβ) …